Management of obesity in advanced chronic liver disease
Obesity has emerged as a major global health challenge and is closely associated with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction- and alcohol-associated liver disease (MetALD). Overall, an increased prevalence of obesity has been reported in patients with advanced chronic liver disease (ACLD), in whom it adversely impacts prognosis. Importantly, increased BMI is recognised as a modifiable risk factor for progression of liver disease, regardless of aetiology. The recent approval of effective and well-tolerated anti-obesity medications offers new opportunities, alongside therapeutic lifestyle changes and bariatric surgery, for the personalised management of patients living with obesity and associated liver disease.
Authors
- Cyrielle Caussy
- S Francque
Institutions
- Université Claude Bernard Lyon 1 (FR)
- University of Antwerp (BE)
- Inserm (FR)
- Antwerp Management School (BE)
- Hospices Civils de Lyon (FR)
- Antwerp University Hospital (BE)
- Province of Antwerp (BE)
- Institut National des Sciences Appliquées de Lyon (FR)
Publication Details
- Journal
- JHEP Reports
- Published
- 2026-01-30
- DOI
- https://doi.org/10.1016/j.jhepr.2026.101749
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Gilead Sciences
- Indian National Science Academy
- Institut National de la Santé et de la Recherche Médicale
- Fonds Wetenschappelijk Onderzoek
- Astellas Pharma
- Hospices Civils de Lyon
- Institut National de la Recherche Agronomique
- Université Claude Bernard Lyon 1
- Universiteit Antwerpen
- Institut National des Sciences Appliquées de Lyon
- Vlaamse regering
- Dr. Falk Pharma